Providence Capital Advisors LLC raised its position in Pfizer Inc. (NYSE:PFE) by 3.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 77,544 shares of the biopharmaceutical company’s stock after acquiring an additional 2,247 shares during the quarter. Pfizer makes up about 2.0% of Providence Capital Advisors LLC’s holdings, making the stock its 6th biggest holding. Providence Capital Advisors LLC’s holdings in Pfizer were worth $3,359,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Wetherby Asset Management Inc. lifted its holdings in Pfizer by 1.2% during the fourth quarter. Wetherby Asset Management Inc. now owns 138,659 shares of the biopharmaceutical company’s stock worth $6,052,000 after acquiring an additional 1,688 shares during the period. Bingham Osborn & Scarborough LLC grew its position in Pfizer by 12.6% during the fourth quarter. Bingham Osborn & Scarborough LLC now owns 16,488 shares of the biopharmaceutical company’s stock valued at $720,000 after buying an additional 1,846 shares during the period. Valeo Financial Advisors LLC increased its holdings in Pfizer by 0.5% during the fourth quarter. Valeo Financial Advisors LLC now owns 114,331 shares of the biopharmaceutical company’s stock worth $4,991,000 after buying an additional 593 shares during the last quarter. Cedar Capital LLC increased its holdings in Pfizer by 7.9% during the fourth quarter. Cedar Capital LLC now owns 14,125 shares of the biopharmaceutical company’s stock worth $617,000 after buying an additional 1,038 shares during the last quarter. Finally, Genovese Burford & Brothers Wealth & Retirement Plan Management LLC raised its position in Pfizer by 36.6% in the fourth quarter. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC now owns 14,939 shares of the biopharmaceutical company’s stock worth $652,000 after acquiring an additional 4,006 shares during the period. Institutional investors own 71.84% of the company’s stock.
In related news, Director Scott Gottlieb acquired 3,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The shares were acquired at an average price of $34.72 per share, with a total value of $104,160.00. Following the acquisition, the director now owns 3,000 shares of the company’s stock, valued at approximately $104,160. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 30,000 shares of the firm’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $44.00, for a total value of $1,320,000.00. Following the completion of the transaction, the insider now owns 80,094 shares of the company’s stock, valued at approximately $3,524,136. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by insiders.
PFE has been the topic of a number of research analyst reports. Bank of America cut shares of Pfizer from a “buy” rating to a “neutral” rating in a research note on Tuesday, July 30th. Goldman Sachs Group restated a “buy” rating and set a $49.00 price target on shares of Pfizer in a research note on Monday, June 17th. Credit Suisse Group reaffirmed a “neutral” rating on shares of Pfizer in a report on Monday, August 12th. DZ Bank upgraded Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price objective on the stock in a research note on Wednesday, August 28th. Finally, JPMorgan Chase & Co. set a $46.00 price objective on Pfizer and gave the company a “neutral” rating in a report on Monday, July 29th. Fifteen investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $45.88.
Shares of PFE stock traded up $0.02 during trading on Wednesday, reaching $37.40. 13,312,549 shares of the company’s stock traded hands, compared to its average volume of 22,412,612. The company has a market capitalization of $203.71 billion, a P/E ratio of 12.47, a PEG ratio of 2.93 and a beta of 0.65. The company has a current ratio of 1.47, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60. The firm’s 50-day moving average is $36.93 and its 200 day moving average is $40.84. Pfizer Inc. has a 1 year low of $33.97 and a 1 year high of $46.47.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The business had revenue of $13.26 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the business earned $0.77 EPS. Pfizer’s revenue was down 1.5% compared to the same quarter last year. As a group, sell-side analysts predict that Pfizer Inc. will post 2.81 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd were issued a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.85%. The ex-dividend date of this dividend was Thursday, August 1st. Pfizer’s payout ratio is currently 48.00%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: Bond
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.